03rd week of 2011 patent applcation highlights part 45 |
Patent application number | Title | Published |
20110015219 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof - The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as a method for identifying (+)-morphinans that may be therapeutically effective by determining whether the (+)-morphinan inhibits the activation of TLR9. Also provided are methods of using the (+)-morphinans comprising TLR9 antagonist activity to treat conditions such as traumatic pain, neuropathic pain, inflammatory disorders, acetaminophen toxicity, autoimmune disorders, neurodegenerative disorders, and cancer. | 2011-01-20 |
20110015220 | MIXED ORL1/MU-AGONISTS FOR THE TREATMENT OF PAIN - The invention relates to the use of compounds which exhibit an affinity for the μ-opioid receptor of at least 100 nM (K | 2011-01-20 |
20110015221 | PHARMACEUTICAL COMPOSITION OF VINFLUNINE WHICH IS INTENDED FOR PARENTERAL ADMINISTRATION PREPARATION METHOD THEREOF AND USE OF SAME - The invention relates to a pharmaceutical composition of vinflunine in the form of a stable sterile aqueous solution of a water-soluble salt of vinflunine with a pH of between 3 and 4. The invention also relates to the method of preparing said composition and to the use thereof as a parenterally-administered medicament for the treatment of cancer. | 2011-01-20 |
20110015222 | Benzoquinolizinium salt derivatives as anticancer agents - 13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium salt compounds of the general formula (I): | 2011-01-20 |
20110015223 | Compounds and methods for treatment of cancer-related anemia - The invention relates to methods and compounds for treating anemia of cancer. In particular, methods for treating anemia of cancer in a subject having cancer, and methods for increasing reticulocytes, increasing hemoglobin, increasing hematocrit, and increasing red blood cell count in subjects having anemia of cancer, wherein such subjects are refractory to treatment with recombinant human erythropoietin (EPO) are encompassed herein. | 2011-01-20 |
20110015224 | COMBINATION OF A CARBOSTYRIL AND CARNITINE - The present invention relates to a medicament for treating occlusive and/or ischemic vascular disorder comprising a carbostyril derivative and carnitine. | 2011-01-20 |
20110015225 | Heterocyclic compound - The present invention provides to a compound having melanin-concentrating hormone receptor antagonistic action and low toxicity, and useful as a agent for the prophylaxis or treatment of obesity and the like. | 2011-01-20 |
20110015226 | Treatment of Energy Utilization Disease - Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon. | 2011-01-20 |
20110015227 | WARMING SENSATE COMPOSITION - The invention relates to a warming sensate composition of (i) a hot component, (ii) a cooling component, and (iii) optionally a bitter component. The weight ratio of (i):(ii) is from 1:3 to 1:100. If a solvent is provided in the composition, the solvent is present in an amount of less than 10 wt % ethanol, based on the total weight of the composition. Also, the bitter component, when used, is present in an amount of less than 0.15% by weight based on the total weight of the composition. | 2011-01-20 |
20110015228 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 2011-01-20 |
20110015229 | METHOD OF TREATING NEUROPATHIC PAIN - A method for treating subjects experiencing neuropathic pain is provided. The method involves the application of a solid-forming local anesthetic formulation to a skin surface of the subject experiencing the neuropathic pain and then maintaining the formulation on the skin surface for a period of time sufficient to allow itself to transdermally deliver the local anesthetic to the subject thereby providing relief from the neuropathic pain within about 45 minutes. | 2011-01-20 |
20110015230 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. | 2011-01-20 |
20110015231 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION - Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (I a) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (I a) or (VIIa). | 2011-01-20 |
20110015232 | Pyrrolydine Derivatives as IAP Inhibitors - The present invention relates to novel IAP inhibitor compounds of: Formula (I). | 2011-01-20 |
20110015233 | Stable Pharmaceutical Omeprazole Formulation for Oral Administration - The present invention is directed to a pharmaceutical solution or syrup formulation for oral administration comprising; omeprazole, a solubilizing agent, a sweetening agent, a flavoring agent, and an antioxidant. | 2011-01-20 |
20110015234 | INDAZOLE DERIVATIVES - The invention is concerned with novel indazole derivatives of formula (I) | 2011-01-20 |
20110015235 | NOVEL PHENYLETHYNYL DERIVATIVES OF 8-AZA-BICYCLO[3.2.1]OCTANE AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel phenylethynyl derivatives of 8-aza-bicyclo[3.2.1]octane useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2011-01-20 |
20110015236 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES - The present invention relates to hydroximoyl-tetrazole derivatives of formula (I), their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. | 2011-01-20 |
20110015237 | SOLID COMPOSITION FOR PEST CONTROL - To provide an anthranilamide formulation compound for improving pest controlling effects. | 2011-01-20 |
20110015238 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES - It is intended to provide highly safe and efficacious blood flow promoters for cauda equina tissues. Among prostaglandin-like compounds having a weak hypotensive effect, compounds having an effect of promoting the blood flow in cauda equina tissues (excluding limaprost) are useful as highly safe blood flow promoters for cauda equina tissues and, therefore, are efficacious in preventing and/or treating lumbar pain, lower limb pain, lower limb palsy, intermittent claudication, vesicorectal failure, hypogonadism, etc. caused by cauda equina injuries. | 2011-01-20 |
20110015239 | INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS - Provided herein are methods for identifying compounds that are inhibitors of a calcium-activated chloride channel. Aminothiophene and aminothiazole compounds, and compositions comprising these compounds, described herein that inhibit efflux of chloride through a calcium-activated chloride channel are useful for treating diseases, disorders, and sequalae of diseases, disorders, and conditions that are associated with aberrantly increased chloride and fluid secretion, for example, secretory diarrhea. | 2011-01-20 |
20110015240 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR - The invention provides a thiazole derivative useful as a VAP-1 inhibitor, as well as a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like, a method of inhibiting VAP-1 in a subject, and a method for the prophylaxis or treatment of VAP-1 associated disease in a subject. The thiazole derivative is a compound represented by the formula (I): R | 2011-01-20 |
20110015241 | SUBSTITUTED HETEROCYCLES AND USE THEREOF - The invention relates to substituted heterocycles, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders. | 2011-01-20 |
20110015242 | PDK-1/AKT SIGNALING INHIBITORS - Use of a new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I for inducing apoptosis in unwanted rapidly proliferating cells, for treating, inhibiting, or delaying the onset of cancer, and for preventing restenosis in a subject that has undergone an angioplasty or stent: | 2011-01-20 |
20110015243 | CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPUTIC AGENTS - The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery. | 2011-01-20 |
20110015244 | BENDAMUSTINE AMPHIPHILIC ANIONIC COMPOSITIONS - The present invention is directed to pharmaceutical compositions comprising bendamustine and one or more amphiphilic anionic compounds and self assembled aggregates, which aggregates exhibit enhanced stability in aqueous solutions, including plasma, are disclosed. The unexpectedly enhanced stability afforded by such aggregates permits patients to be treated with bendamustine in lower and/or with less frequent dosages or to improve its therapeutic effect while using the same as presently used treatment protocol. | 2011-01-20 |
20110015245 | BENDAMUSTINE AMPHIPHILIC CATIONIC COMPOSITIONS - The present invention is directed to pharmaceutical compositions comprising bendamustine and one or more amphiphilic cationic compounds, which self assemble to form aggregates. The exhibiting enhanced stability in aqueous solutions, including plasma. The unexpectedly enhanced stability afforded by such aggregates permits patients to be treated with bendamustine in lower and/or with less frequent dosages or to improve its therapeutic effect while using the same as presently used treatment protocol. | 2011-01-20 |
20110015246 | LOFEXIDINE ENANTIOMERS FOR USE AS A TREATMENT FOR CNS DISEASE AND PATHOLOGIES AND ITS CHIRAL SYNTHESIS - The invention relates to methods for treatment of CNS disease and pathologies using non-racemic mixtures of lofexidine enantiomers. The invention also relates to processes for the manufacture of chirally pure enantiomers of lofexidine. | 2011-01-20 |
20110015247 | NOVEL CRYSTALLINE FORM OF CARVEDILOL DIHYDROGEN PHOSPHATE AND RELATED PROCESSES - The present patent application relates to a novel crystalline form (Form S) of Carvedilol dihydrogen phosphate and a process for its preparation. It also relates to an improved process for the preparation of Carvedilol dihydrogen phosphate. | 2011-01-20 |
20110015248 | SUBSTITUTED HETEROCYCLES - The present invention relates to substituted heterocycles, processes for their preparation, and their use in medicaments, especially for the treatment of inflammatory disease, i.e. asthma, or cancer. | 2011-01-20 |
20110015249 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND OTHER ANGIOGENESIS-RELATED DISEASES - The present invention provides nucleic acid molecules that modulate the expression of molecules in the angiopoietin/Tie2 signaling pathway. Methods of using the nucleic acid molecules are also provided. | 2011-01-20 |
20110015250 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell. | 2011-01-20 |
20110015251 | RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of human immunodeficiency virus (HIV) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of HIV genes. The small nucleic acid molecules are useful in the treatment of HIV infection, AIDS, and/or disease and conditions related to HIV infection and/or AIDS in a subject or organism. | 2011-01-20 |
20110015252 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE - This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene. | 2011-01-20 |
20110015253 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 2011-01-20 |
20110015254 | PTPH1 Inhibitors for the Treatment of Alzheimer's Disease - The present invention relates to the use of PTPH1 inhibitors in the prevention or treatment of Alzheimer's Disease, or a symptom thereof. The present invention also relates to a method of identifying compounds useful in the prevention or treatment of Alzheimer's Disease, or a symptom thereof. | 2011-01-20 |
20110015255 | TREATMENT OF AN INFECTION BY AN RNA VIRUS DUE TO AN RNA DEPENDENT RNA POLYMERASE - The present invention concerns a simple RNA strand, which includes, from extremity 3′ to extremity 5′, (i) a sequence of complementary nucleic acid to the non-coding region 5′ (5′UTR) of the genomic RNA (strand (+)) of the hepatitis C virus (VHC) or another RNA virus replicating thanks to an RNA dependent RNA polymerase, the nucleic acid sequence of which allows the replication of said simple RNA strand molecule by the replication complex of said virus, (ii) the complementary nucleic acid sequence of a corresponding nucleic acid sequence from the site of internal entry of the ribosome (1RES), and (iii) the complementary nucleic acid sequence of a suicide gene or a coding gene for a protein interfering with the replication of the VHC virus or another RNA virus replicating thanks to an RNA dependent RNA polymerase; an ADN molecule allowing the transcription of said simple RNA strand molecule; a vector of nucleic acids including said molecules of nucleic acids; and a pharmaceutical compound including said molecules of nucleic acids or said vector of nucleic acid. | 2011-01-20 |
20110015256 | DELIVERY OF RESTRICTION ENDONUCLEASES TO TREAT HIV, CANCER, AND OTHER MEDICAL CONDITIONS - A method of treating a medical condition caused by the presence of an undesired DNA sequence in a predetermined cell type of a subject by administering to the subject one or more restriction endonucleases to specifically cleave the undesired DNA sequence. | 2011-01-20 |
20110015257 | Hypoxia Inducible VEGF Plasmid for Ischemic Disease - Plasmids useful for treating ischemic disease, such as ischemic heart disease, are described. The plasmids express vascular endothelial growth factor (VEGF) under the control of a promoter (RTP801) that is up-regulated under hypoxic conditions. Pharmaceutical compositions for treating ischemic disease include mixtures of the hypoxia-regulated VEGF plasmids and pharmaceutically acceptable carriers. Methods for treating ischemic disease include administering such pharmaceutical compositions to a person in need of such treatment. | 2011-01-20 |
20110015258 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 2011-01-20 |
20110015259 | TLE3 AS A MARKER FOR CHEMOTHERAPY - Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer. | 2011-01-20 |
20110015260 | ANTI-MALARIAL PHARMACEUTICAL COMPOSITION - The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions. | 2011-01-20 |
20110015261 | USE OF A COMPOSITION COMPRISING AT LEAST ONE BETA-BLOCKER FOR THE TREATMENT OF SLEEP DISORDERS - A composition comprising specific beta-blockers such as bisoprolol and nebivolol for the treatment of insomnia and/or another sleep disorder. The composition should be given in such an amount that it causes a less than 40% decrease in the amount of aMT6s in complete nocturnal urin. The composition can be a combination treatment comprising a specific beta-blocker in combination with another known drug e.g., melatonin with similar effect for treatment of insomnia. | 2011-01-20 |
20110015262 | Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition - Methods and compositions for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using combination of compounds, or a bifunctional compound, that inhibits both fatty acid metabolism and glycolysis. In particular, the invention combines or links a glycolysis inhibitor that is, or that is derived from, hypoglycin A (also referred to as hypoglycine A) and a fatty acid metabolism inhibitor. Preferably, the invention provides bifunctional compounds that link a moiety having the functionality of an oxirane carboxylic acid compound to a moiety having the functionality a hypoglycin A derivative. In specific embodiments, the invention provides a bifunctional compound that links a moiety having the functionality of etomoxir to a moiety having the functionality of hypoglycin A. | 2011-01-20 |
20110015263 | THERAPEUTIC DELIVERY OF CARBON MONOXIDE - Compounds, pharmaceutical compositions and methods for the therapeutic delivery of carbon monoxide to humans and other mammals that employ transition metal complexes having at least a substituted cyclopentadienyl, indenyl or fluorenyl ligand and two or more carbonyl ligands. | 2011-01-20 |
20110015264 | INTRAMUSCULAR ANTIVIRAL TREATMENTS - The invention provides unit dosage forms, kits, and methods useful for treating viral infections. | 2011-01-20 |
20110015265 | METHOD FOR CONTROLLING DISEASES ON TURFGRASS - The present invention provides a method for controlling diseases on turfgrass which comprises applying to turfgrass that has been cut back an effective amount of a compound of formula ( | 2011-01-20 |
20110015266 | LYOPHILIZED NANOEMULSION - The present invention relates to a lyophilised nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilised nanoemulsion by redispersion, and to a process for the preparation of the lyophilised nanoemulsion. | 2011-01-20 |
20110015267 | METHODS FOR THE PREPARATION AND USE OF AQUEOUS SOLUTIONS OF MAGNESIUM VALPROATE HYDRATE AND L-CARNITINE - The present invention relates to methods for preparing liquid valproate compositions comprising solutions of a magnesium valproate and L-carnitine in water and administering said compositions to a subject in need of treatment with valproate and L-carnitine. The compositions of the invention are particularly useful treatments for infants, young children, women of child-bearing age, the aging, institutionalized patients, and patients having dysphagia who are receiving valproate treatment and are at high risk for valproate-related L-carnitine deficiency and cellular dysfunction and hepatotoxicity related thereto. | 2011-01-20 |
20110015268 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising a docusate; an osmotic laxative; and a benzoate. | 2011-01-20 |
20110015269 | PROCESS FOR THE PREPARATION OF DIACERIN - The invention concerns a new process for the preparation of high purity diacerein, by oxidisation of the protected aloe-emodin in the presence of an oxidising system and radical catalyst and subsequent substitution of the protector groups with acetyl groups. | 2011-01-20 |
20110015270 | Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 2011-01-20 |
20110015271 | TOPICAL NEPAFENAC FORMULATIONS - Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration. | 2011-01-20 |
20110015272 | Sirtuin 1 and the Treatment of Neurodegenerative Diseases - This invention relates to bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable salts and their use in the modulation of Sirtuin 1 (Sirt1) and there use in neuroprotection for subject suffering from neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies, and in the manufacture of medicaments for such Sirt1 modulation and neuroprotection. | 2011-01-20 |
20110015273 | STABLE PHARMACEUTICAL AQUEOUS COMPOSITIONS - The present invention refers to an parenterally administerable aqueous formulation containing paracetamol. For enhancing stability the formulation contains a sulphur containing antioxidant, preferably sodium metabisulfite. For making the formulation more soluble it contains hydroxy propyl beta cyclodextrin. The composition is used as analgesic. | 2011-01-20 |
20110015274 | FORM OF AN AMINOINDAN MESYLATE DERIVATIVE - The present disclosure relates generally to rasagiline mesylate with improved flowability and with advantageously reduced stickiness, to processes for the preparation thereof, and to the use thereof for milling and for preparing pharmaceutical formulations. Methods for improving the flowability and/or alleviating the stickiness of rasagiline mesylate having a very poor flowability and/or showing undesirable stickiness are also disclosed. | 2011-01-20 |
20110015275 | Materials and Methods for Improving Alcohol Metabolism and Alleviating the Effects of Hangovers - The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride. | 2011-01-20 |
20110015276 | THERAPEUTICAL USES OF INECALCITOL - The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D relevant disease comprising administering inecalcitol at doses comprised between 1 mg/day and 100 mg/day to a human patient in need thereof. | 2011-01-20 |
20110015277 | METHOD OF PRODUCING EGG YOLK BASED FUNCTIONAL FOOD PRODUCT AND PRODUCTS OBTAINABLE THEREBY - The present invention relates to the field of food products, especially food products specifically designed for providing health benefits beyond the basic function of nutrition for a subject consuming the product on a regular basis, e.g. on a daily basis. According to the present invention eggs are produced, in particular chicken eggs, that are enriched in one or more pharmacologically active nutrients. The egg yolk obtained from the aforementioned eggs can suitably be used in high amounts as a component of a functional food product having all the characteristics that are normally required for such functional food products. A preferred example of a food product in accordance with the invention is a ready to drink shot containing approximately one whole egg yolk in a volume as small as 100 ml. | 2011-01-20 |
20110015278 | PHYTOL AS A CHOLESTEROL LOWERING AGENT - Phytol (3,7,11,15-Tetramethyl-2-hexadecen-1-ol), or derivates thereof, of natural or synthetic origin are used as active ingredient in formulations to lower serum levels of triglycerides and/or cholesterol. Phytol can be administered to patients with disease conditions related to increased levels of cholesterol or triglycerides such as type II diabetes, obesity or other patients in risk of cardiovascular diseases due to elevated cholesterol levels. Phytol can also be administered to healthy individuals to maintain normal levels of serum cholesterol. | 2011-01-20 |
20110015279 | SKIN CARE COMPOSITION - The invention relates to skin care compositions containing special polyurethanes for application to the skin. The invention also relates to the use of said polyurethanes for producing skin care products. | 2011-01-20 |
20110015280 | AMPHOLYTIC COPOLYMER, PRODUCTION THEREOF, AND USE OF THE SAME - The present invention relates to an ampholytic copolymer, to a process for its preparation, to cosmetic or pharmaceutical compositions which comprise at least one such ampholytic copolymer, and to further uses of these copolymers. | 2011-01-20 |
20110015281 | APPARATUS AND METHOD FOR CARRYING OUT CHEMICAL AND PHYSICAL MATERIALS TRANSFORMATIONS - Reactor for carrying out chemical and physical materials transformations, which comprises a reaction space enclosed by a reactor housing, where the reactor housing has at least two lateral fluid inlets having adjustably mounted nozzles which include an angle of about 20-160 degrees and through which fluid jets which impinge on one another at a common collision point within the reaction space are passed and the reactor has a fluid outlet at the bottom of the reaction space, which is characterized in that—an exchangeable bottom plate•which has a hole as fluid outlet and•on which moveably supported spheres are located so as to block the original path of the individual fluid jets in the unaligned state rests on the bottom of the reaction space and—a half shell standing upright on the bottom of the reaction space is located between each moveably supported sphere and the wall of the reactor space and—bottom plate, half shell and moveably supported spheres comprise one or more hard materials. | 2011-01-20 |
20110015282 | PRODUCTION METHOD OF LIQUID HYDROCARBONS FROM NATURAL GAS - In a so-called GTL process for producing liquid hydrocarbons containing fuel oil by producing synthesis gas from natural gas, subsequently producing Fischer-Tropsch oil from the obtained synthesis gas by way of Fischer-Tropsch synthesis and upgrading the produced Fischer-Tropsch oil, the synthesis gas produced from a synthesis gas production step is partly branched at a stage prior to getting to a Fischer-Tropsch oil production step and high-purity hydrogen is separated and produced from the synthesis gas entering the branch line. All the separated high-purity hydrogen is supplied to an upgrading reaction step and consumed as hydrogen for an upgrading reaction. Additionally, the synthesis gas entering the branch line is subjected to a water gas shift reaction to raise the hydrogen concentration before the step of separating and producing high-purity hydrogen and the residual gas left after the separation may be circulated to the synthesis gas production step as raw material for producing synthesis gas. | 2011-01-20 |
20110015283 | PROCESS FOR PRODUCING FLUOROPOLYMER, AND FLUORINATED ION EXCHANGE MEMBRANE - A polymerization medium having small ozone depletion potential and small global warming potential and having a small chain transfer constant is used, to efficiently produce a fluoropolymer having a high molecular weight and having excellent heat resistance, solvent resistance, chemical resistance, etc. | 2011-01-20 |
20110015284 | RUBBER DE-VULCANISATION - The present invention relates to a method for preferentially breaking cross-links in a vulcanized rubber, thereby de-vulcanizing the rubber, by the use of a supercritical fluid, such as carbon dioxide The supercritical fluid causes swelling of the said vulcanized rubber material, wherein the time of swelling is not more than 50% of the time required for full volume equilibrium swelling of the rubber in said supercritical fluid and the swelling is followed by a rapid reduction of the supercritical fluid pressure The cross links ( | 2011-01-20 |
20110015285 | FOAMABLE COPOLYMERS BASED ON RENEWABLE RAW MATERIALS - The invention relates to a process for the production of foamable copolymers, to foamable copolymers and to foamable polymer structures based on itaconic acid, mesaconic acid, fumaric acid, maleic acid, aconitic acid, and glutaconic acid. | 2011-01-20 |
20110015286 | PROCESS FOR THE PREPARATION OF EXPANDABLE POLYSTYRENE - The present invention relates to a process for the preparation of expandable polystyrene comprising the following steps: i | 2011-01-20 |
20110015287 | FOAMED MATERIALS COMPRISING A MATRIX HAVING A HIGH HIGHBLOCK CONTENT AND PROCESS FOR PREPARING THEM - Foamed material having a density of less than 100 kg/m | 2011-01-20 |
20110015288 | POLYMER FOAMS - A process for producing polymer foams by precise control of their morphology through use of microfluidic processes, foams produced in this way and use thereof. | 2011-01-20 |
20110015289 | INSULATION BOARDS AND METHODS FOR THEIR MANUFACTURE - A method for producing polyisocyanurate insulation foams, the method comprising contacting an A-side stream of reactants that includes an isocyanate with a B-side stream of reactants that include a polyol and a blowing agent, where the blowing agent includes isopentane and n-pentane in a substantial absence of cyclopentane. | 2011-01-20 |
20110015290 | USE OF METAL SALTS OF A CARBOXYLIC ACID IN THE PRODUCTION OF POLYURETHANE SYSTEMS - A catalyst system which is suitable for catalyzing the production of polyurethane systems is provided. The catalyst system contains a metal salt of a carboxylic acid to whose carbonyl carbon a hydrogen atom or a hydrocarbon radical is bound, with the proviso that the carboxylic acid does not have exclusively a single ethyl or n-propyl branch in the 2 position. | 2011-01-20 |
20110015291 | PREPOLYMERS BASED ON DI- OR POLYISOCYANATES AND FORMAMIDE-TERMINATED LOW MOLECULAR WEIGHT COMPOUNDS, PROCESSES FOR PREPARING THE SAME AND USES THEREOF - Prepolymers, which are accessible from formamides of low molecular weight di- or triamines (formamide-terminated low molecular weight compounds) and di- or polyisocyanates, of the general formula (II): | 2011-01-20 |
20110015292 | PREPOLYMERS MADE FROM NATURAL OIL BASED POLYOLS - A prepolymer and products made from the preopolymer is described. The prepolymer includes the reaction product of at least one isocyanate and at least one natural oil based polyol. The natural oil based polyol includes at least two natural oil moieties separated by a molecular structure having an average of at least about 19 ether groups between any 2 of the natural oil moieties or by a polyether molecular structure having an equivalent weight of at least about 480. | 2011-01-20 |
20110015293 | POLYETHER NATURAL OIL POLYOLS AND POLYMERS THEREOF - A polyether NOP comprises at least two natural oil moieties separated by a molecular structure having at least about 19 ether groups or by a polyether molecular structure having an equivalent weight of at least about 480, said polyol referred to hereinafter as a polyether NOP. The polyether NOP is preferably prepared by a process comprising admixing at least one polyether initiator having an equivalent weight of at least about 480 or at least about 19 ether groups per active hydrogen group with at least one natural oil or derivative thereof under reaction conditions such that at least one polyether NOP is formed. The invention includes reaction products of the polyether NOP or combinations thereof, optionally and preferably in admixture with at least one other polyol which preferably includes at least one polyether polyol and at least one monomer reactive therewith, preferably at least one polyisocyanate to form a polyurethane, preferably in the form of a foam, especially a high resilience foam. The invention includes articles comprising at least one polyether NOP, at least one polymer thereof, or at least one foam thereof. | 2011-01-20 |
20110015294 | ENERGY RAY-CURABLE INK COMPOSITION - The present invention provides an energy ray-curable ink composition excellent in the continuous discharge property, and excellent in curability and adherability. The present invention relates to an energy ray-curable ink composition which contains a coloring agent, contains only a monofunctional monomer having an acrylic equivalent of 300 or less, and having one ethylenic double bond in one molecule, and a polyfunctional monomer having an acrylic equivalent of 150 or less, and having two or more ethylenic double bonds in one molecule as a polymerizable compound, contains an α-aminoalkylphenone compound and a thioxanthone compound as a photopolymerization initiator, and contains a silicone compound having a polydimethylsiloxane structure as a surface conditioner. | 2011-01-20 |
20110015295 | ADDITIVE MIXTURES FOR AGRICULTURAL ARTICLES - Disclosed are 2,6-bis[octadecyloxy]anthraquinone, 1-(4,6-bis[dibutylamino]-[1,3,5]-triazin-2-ylamino)-anthraquinone, 2-(4,6-bis[dibutylamino]-[1,3,5]-triazin-2-ylaminoyanthraquinone, 2,6-bis[4,6-bis[dibutylamino]-[1,3,5]-triazin-2-yloxy]-anthraquinone, 2-(2-ethyl-hexyloxy)-1-octadecyloxy-anthraquinone, 1,2-bis[octadecyloxy]anthraquinone, 1,2-bis[2-ethyl-hexyloxy]anthraquinone, 1,2-bis[octyloxy]anthraquinone, 1,5-bis[2-ethyl-hexyloxy]anthraquinone, 9,10-dioxo-9,10-dihydro-anthracene-2-sulfonic acid dodecylamide, 2,6-bis[stearoyloxy]anthraquinone and bis[9,10-dioxo-9,10-dihydro-anthracene-2-sulfonic acid]-1′,12′-dodecandiyldiamide. | 2011-01-20 |
20110015296 | SUPERABSORBENT POLYMER COMPOSITE PARTICLES AND PROCESSES THEREFORE - Superabsorbent material, comprising clay-crosslinked superabsorbent polymers, obtainable by polymerizing in a spray-stream, polymerizable compounds in the presence of a polymerization initiator system, and nano-sized or individual clay particles, which are all introduced into a vessel by a spraying step in the form of a said spray-stream thereof, whereby said clay particles crosslink said polymers during polymerization. The invention also relates to such a process and absorbent articles comprising such superabsorbent material. | 2011-01-20 |
20110015297 | NANO STRUCTURED UV ABSORBERS - The present invention relates to an UV absorbing polymer composition comprising effective amounts of (a1) a nanoparticulate oxide selected from oxides of the groups 4 and 12 of the periodic table, wherein the oxide is doped with In, Ga and/or Al, and (b1) a UV stabilizing/absorbing substance comprising a sterically hindered amine and/or a polymeric hydroxyphenyl-triazine; or (a2) a nanoparticulate oxide selected from oxides of the groups 4 and 12, and (b2) a UV light stabilizing substance comprising a N-oxygen-substituted sterically hindered amine. Furthermore, the present invention relates to a polymer comprising said composition and the use of said composition as a UV absorber in polymers, particularly in agricultural films or packaging films. Finally, the present invention relates to a process for producing doped nanoparticulate metal oxides. | 2011-01-20 |
20110015298 | PROCESS FOR MAKING CATIONIC HYDROPHILIC SILOXANYL MONOMERS - The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain cationic monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices. Such properties include the ability to extract the polymerized medical devices with water. This avoids the use of organic solvents as is typical in the art. The polymeric compositions comprise polymerized cationic hydrophilic siloxanyl monomers prepared by the process disclosed herein. | 2011-01-20 |
20110015299 | PROCESS FOR PREPARING LATEX PAINTS CONTAINING BIOCIDES - A process for incorporating water insoluble biocides in latex paint products. The process comprises adding the biocide to the dispersion phase. | 2011-01-20 |
20110015300 | METHODS AND SYSTEMS FOR COATING A SURFACE - A coating system and method are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two of the cyclic groups may include quaternary ammonium moieties. In some embodiments, a method may include applying a coating to a surface. The coating may be antimicrobial. A coating may include antimicrobial bridged polycyclic compounds. Bridged polycyclic compounds may include quaternary ammonium compounds. Bridged polycyclic compounds based coating systems may impart self-cleaning properties to a surface. | 2011-01-20 |
20110015301 | MIXTURES COMPRISING BRANCHED OLIGOMERIC OR POLYMERIC COMPOUNDS, AND PREPARATION AND USE THEREOF - Mixtures comprising
| 2011-01-20 |
20110015302 | METHOD FOR PRODUCING MODIFIED CONJUGATED DIENE POLYMER, MODIFIED CONJUGATED DIENE POLYMER, AND RUBBER COMPOSITION - A method for producing a modified conjugated diene polymer includes a modification step (A) that subjects a conjugated diene polymer having a cis-1,4-bond content of 98.5% or more and possessing an active end to a modification reaction to introduce an alkoxysilane compound having two or more reactive groups including an alkoxysilyl group into the active end of the conjugated diene polymer, and a condensation step (B) that subjects the residue of the alkoxysilane compound introduced into the active end to a condensation reaction in the presence of a condensation catalyst that includes at least one element among the elements of the groups 4A, 2B, 3B, 4B, and 5B in the periodic table. The method can produce a modified conjugated diene polymer that exhibits low heat build-up and excellent wear resistance. | 2011-01-20 |
20110015303 | Rubber Composition in Particular for the Manufacture of Tires - A rubber composition, in particular intended for the manufacture of tires, based on at least a predominant elastomer, chosen from the group consisting of butyl rubbers, essentially unsaturated diene elastomers, essentially saturated diene elastomers and the mixtures of these elastomers, and a reinforcing filler, characterized in that the composition also comprises at least one inert filler chosen from silicon-based lamellar mineral fillers and a nonfunctionalized polyisobutylene oil, having a molecular weight of between 200 g/mol and 40 000 g/mol, present in a proportion of between 2 and 50 phe. | 2011-01-20 |
20110015304 | Modification of the Surface Chemistry of Macromolecular Species in the Presence of a Conjugated Guanidine - The present invention relates to a method for preparing macromolecular species with a modified surface, comprising a step (e) in which macromolecular species (M), initially carrying —OH and/or —SH functions, are brought into contact with: a catalyst (C) carrying at least one conjugated guanidine function; and reactive species (E), comprising reactive groups including: (i) at least one group including an a,b-unsaturated carbonyl group C═C—C═O and/or an a,b-unsaturated thiocarbonyl group C═C—C═S; and/or (ii) at least one heterocyclic group comprising from 3 to 5 ring members, said group being selected from cyclic ethers, cyclic thioethers and aziridine rings; and/or (iii) at least one group selected from isocyanate —N═C═O or thioisocyanate —N═C═S groups, and trivalent groups of formula >C═CZ—, where Z is an electron-withdrawing group. The invention also relates to the macromolecular species with a modified surface that are obtained in this context. | 2011-01-20 |
20110015305 | METHOD FOR PREPARING SILICONE COMPOSITION - A silicone composition comprising an organopolysiloxane containing at least two silicon-bonded alkenyl and/or hydroxyl groups in the molecule and a filler having a BET surface area of at least 10 m | 2011-01-20 |
20110015306 | CEMENTITIOUS COMPOSITIONS FOR DECREASING THE RATE OF WATER VAPOR EMISSIONS FROM CONCRETE AND METHODS FOR PREPARING AND USING THE SAME - Cementitious compositions and processes for preparing and using the cementitious compositions are provided. The cementitious compositions are characterized by the property of a reduced or an attenuated water vapor emission of a hardened concrete formed therefrom. | 2011-01-20 |
20110015307 | WOODY SYNTHETIC RESIN COMPOSITION HAVING IMPROVED WEATHER RESISTANCE AND MOLDED BODY THEREOF - The invention provides a woody synthetic resin composition having excellent weather resistance, and a molded body thereof. | 2011-01-20 |
20110015308 | COLORANT CONCENTRATES FOR THERMOPLASTIC BIOFIBER COMPOSITES - Color concentrates for thermoplastic biofiber composites are disclosed. The concentrates employ three factors to achieve concentrated delivery of color to the processing machine and excellent and substantially uniform dispersion of color in the processing machine: melt flow of the concentrate exceeding at least 4 g/10 min. using ASTM D-1238; pellet size of the concentrate such that at least 50 pellets weigh less than one gram; and weight percent of the colorant ingredients in the concentrate exceeding at least 30 weight percent. | 2011-01-20 |
20110015309 | THERMOPLASTIC STARCH COMPOUNDS - The invention relates to a homogeneous, non-dried, melt-extruded thermoplastic compound containing 30-60% by weight dry substance of native or chemically modified starch, maximum 11% by weight dry substance of at least one other biopolymer selected from the group consisting of carrageenan or a different polysaccharide or a protein, 20-45% by weight dry substance of at least one softener and a maximum of 20% by weight water. Said compound can be used, advantageously, to produce molded bodies such as soft capsules with increased impact resistance. | 2011-01-20 |
20110015310 | POLYESTER FIBERS, PROCESS FOR PRODUCING THE SAME, AND TEXTILE STRUCTURE EMPLOYING THE SAME - For the purpose of letting a fiber structure formed of polyester-based fibers have high hydrolysis resistance, spun fibers are treated by a terminal blocking agent, to have the terminal blocking agent taken up inside the fibers, for blocking the terminal carboxyl groups. | 2011-01-20 |
20110015311 | ASPHALT COMPOSITIONS AND THE PREPARATION THEREOF - Asphalt compositions and methods of forming such are described herein. The asphalt compositions and methods of forming such are generally adapted to enable open air processing while producing asphalt compositions that exhibit properties capable of meeting SUPERPAVE™ specifications. | 2011-01-20 |
20110015312 | BINDER COMPOSITION AND ASPHALT MIXTURE - A binder composition and asphalt mixture that are suitably used to prepare asphalt pavements are disclosed. The binder composition comprises a resin of vegetable origin, an oil of vegetable origin and a polymer, and the polymer comprises functional groups chosen from carboxylic acid anhydride, carboxylic acid and epoxide groups. | 2011-01-20 |
20110015313 | RECLAIMED ASPHALT PAVEMENT CONTAINING POLYPHOSPHORIC ACID MODIFIED BINDER - Pavement compositions containing increased amounts of reclaimed asphalt pavement (RAP) are described. Addition of polyphosphoric acid (PPA) to pavement compositions containing RAP allows increased RAP content in road pavements while maintaining acceptable properties in the final pavement composition. Methods for producing road pavements containing RAP and PPA are also provided. | 2011-01-20 |
20110015314 | ULTRAVIOLET ABSORBENT AND PRODUCTION METHOD OF THE SAME - An ultraviolet absorbent containing a compound represented by the following formula (I), having an aluminum ion in a concentration of less than 2 ppm, and an iron ion in a concentration of less than 2 ppm. | 2011-01-20 |
20110015315 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES - The present invention relates to novel processes for the preparation of sterically hindered amine ethers by the transformation of a corresponding oxo-piperidin to a hydroxy or amino substituted sterically hindered amine ether and the preparation of a N-propoxy or N-propenoxy substituted sterically hindered amine and some novel compounds obtainable by these processes. The compounds made by these processes are particularly effective in the stabilization of polymer compositions against harmful effects of light, oxygen and/or heat and as flame-retardants for polymers. | 2011-01-20 |
20110015316 | Polypropylene Impact Copolymers Having High Melt Flow and Izod Ductibility - Impact copolymers that comprise a continuous phase comprising a propylene-based polymer and a discontinuous rubber phase comprising a propylene/ethylene copolymer. The impact copolymers can have a fraction copolymer value (Fc) of at least 35, an ethylene content (Ec) of at least 38, a melt flow rate of at least 50 g/10 min and a notched Izod impact strength at 23° C. of at least 615 J/m. | 2011-01-20 |
20110015317 | POLY(METH)ACRYLIMIDE HAVING IMPROVED OPTICAL AND COLOR PROPERTIES, PARTICULARLY UNDER THERMAL LOAD - Process for preparing moulding materials MM with improved optical and colour properties, consisting of a polymer PM which contains units of the formula I | 2011-01-20 |
20110015318 | RESIN COMPOSITIONS FOR WRINKLE PATTERN PAINTS - Disclosed is a resin composition comprising (A) hydroxyl group containing acrylic resin having a hydroxyl group value of from 5 to 200 mgKOH/g and a number average molecular weight of from 500 to 20,000, (B) hexakisalkoxymethylated melamine resin, (C) de-watering agent, (D) blocked sulfonic acid compound which has been blocked with a tertiary amine compound of boiling point from 50 to 300° C. in which the mol ratio with respect to the sulfonic acid is from 0.2 to 0.9, (E) silicate compound and (F) at least one type of material selected from among (a) organic resin particle of average particle diameter not more than 40 μm, (b) inorganic glass particles of average particle diameter not more than 100 μm and (c) inorganic fibers of average length not more than 300 μm. | 2011-01-20 |